The Real-World Impact of CAR T-Cell Therapy in Large B-Cell Lymphoma : Episode 7

Bridging Therapy With CAR T-Cell Therapy in LBCL

April 19, 2024

By Caron Jacobson, MD
Miguel-Angel Perales, MD

News

Video

Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.

EP: 1.The Expanding Utility of CAR T-Cell Therapy in LBCL

EP: 2.Sequencing With CAR T-Cell Therapy for LBCL

EP: 3.CAR T-Cell Therapy as a Second-Line Treatment for LBCL

EP: 4.Understanding Malignancy Risks With the Use of CAR T-cell Therapies

EP: 5.Real World Findings for Liso-Cel in LBCL From the Cell Therapy Consortium

EP: 6.Expert Perspective on Real-World Follow-Up Analyses of Liso-Cel in LBCL

EP: 7.Bridging Therapy With CAR T-Cell Therapy in LBCL

EP: 8.The Impact of Real-World Analyses in the Utilization of CAR T-Cell Therapy in LBCL

EP: 9.The Future of CAR T-Cell Therapy in LBCL

EP: 10.Back to the Bench: Exploring the Potential of CAR T-Cell Therapy in Oncology

Recent Videos

Tami John, MD

Tami John, MD

Tami John, MD

Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital

Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center

Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences

Related Content

Around the Helix: Cell and Gene Therapy Company Updates – July 2, 2025

Around the Helix: Cell and Gene Therapy Company Updates – July 2, 2025

Noah Stansfield

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Tami John, MD

Considerations for β-Thalassemia Gene Therapy in the Real World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, discussed considerations for using beti-cel and exa-cel for TDT in the clinic.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

Survival Outcomes Found to Be Comparable for Axi-Cel, Liso-Cel, and Tisa-Cel in Real-World DLBCL Data

Survival Outcomes Found to Be Comparable for Axi-Cel, Liso-Cel, and Tisa-Cel in Real-World DLBCL Data

Caroline Seymour

The 3 FDA-approved CAR T-cell therapies showed comparable survival outcomes in DLBCL over a 3-year period.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – June 27, 2025

Noah Stansfield

Review top news and interview highlights from the week ending June 27, 2025.

Related Content

Around the Helix: Cell and Gene Therapy Company Updates – July 2, 2025

Around the Helix: Cell and Gene Therapy Company Updates – July 2, 2025

Noah Stansfield

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Tami John, MD

Considerations for β-Thalassemia Gene Therapy in the Real World

Tami John, MD;Noah Stansfield

Tami John, MD, a clinical associate professor at Stanford Medicine, discussed considerations for using beti-cel and exa-cel for TDT in the clinic.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

Survival Outcomes Found to Be Comparable for Axi-Cel, Liso-Cel, and Tisa-Cel in Real-World DLBCL Data

Survival Outcomes Found to Be Comparable for Axi-Cel, Liso-Cel, and Tisa-Cel in Real-World DLBCL Data

Caroline Seymour

The 3 FDA-approved CAR T-cell therapies showed comparable survival outcomes in DLBCL over a 3-year period.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind – June 27, 2025

Noah Stansfield

Review top news and interview highlights from the week ending June 27, 2025.

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.